2Rove KO,Crawford ED.Metastatic cancer in solid tumors and clinical outcome:skeletal-related events[J].Oncology (Williston Park),2009,23(Suppl 5):21-27.
3Ricciardi S,Marinis F.Treatment of bone metastases in lung cancer:the actual role of zoledronic acid[J].Rev Recent Clin Trials,2009,4(3):205-211.
4Fitch M,Maxwell C,Ryan C,et al.Bone metastases from advanced cancers:clinical imp lications and treatment options[J].Clin J Oncol Nurs,2009,13(6):701-710.
5Clark JC,Dass CR,Choong PF.Current and future treatments of bone metastases[J].Expert OpinEmerg Drugs,2008,13(4):609-627.
7Beek ER,Cohen LH,Leroy IM,et al.Dif ferentiating the mechanism of antiresorptive action of nitrogen containing bisphosphonat-es[J].Bone,2003,33(5):805-811.
1Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase Ⅲ, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol,2003,21 (16) :3150-3157.
2Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate.Clin Ther, 2003,25 ( 11 ) :2669-2708.
3Saad F. Treatment of bone complications in advanced prostate cancer:rationale for bisphosphonate use and results of a phase Ⅲ trial with zoledronic acid. Semin Oncol, 2002,29 (6 Suppl 21 ) : 19-27.
4Bilston LE, Little DG, Smith NC, et al. Zoledronic acid improves the mechanical properties of normal and healing bone. Clin Biomech ( Bristol, Avon), 2002,17(9-10) : 716-718.
5Rosen L, Harland SJ, Oosterlinck W. Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors. Am J Clin Oncol, 2002,25 (6 Suppl 1 ) :S19-24.
6Lipton A, Small E, Saad E, et al. The new bisphosphonate, Zometa(zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest,2002,20( Suppl 2) :45-54.
7Rosen LS,Gordon D,Kaminski M,et at. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 2003,98(8) :1735-1744.
8Weinfurt KP, Castel LD, Li Y,et al. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care, 2004,42 ( 2 ) :164-175.
9Rosen LS,Gordon DH,Dugan W Jr,et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer, 2004 , 100( 1 ) :36-43.
10Harvey HA. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy. Semin Oncol, 2004,31 (6 Suppl 12) :23-30.
7YehJ Y, Huang W J, Kan S F, et al. Effects of bufalin and einobufagin on the proliferation of androgen dependent and independent prostate cancer cells[J]. Prostate,2003,54(2) : 112- 124.
8Facchini G,Caraglia M,Santini D,Nasti G,Ottaiano A,Striano S,Maiolino P,Ruberto M,Fiore F,Tonini G,Budillon A,Iaffaioli R V,Zeppetella G L.The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). Journal of experimental & clinical cancer research : CR . 2007
9JCM Clark,CR Dass,Peter FM Choong.Current and future treatments of bone metastases. Expert Opinion on Emerging Drugs . 2008
10Zoledronic acid repolarizes tumour‐associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway(J)Journal of Cellular and Molecular Medicine . 2010 (12)
